Pathstone Holdings’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$675K Buy
8,620
+251
+3% +$17.1K ﹤0.01% 1716
2026
Q1
$541K Sell
8,369
-354
-4% -$25K ﹤0.01% 1721
2025
Q4
$587K Sell
8,723
-330
-4% -$22.2K ﹤0.01% 1682
2025
Q3
$664K Buy
9,053
+229
+3% +$15.2K ﹤0.01% 1627
2025
Q2
$459K Sell
8,824
-282
-3% -$16K ﹤0.01% 1756
2025
Q1
$581K Buy
9,106
+227
+3% +$13.2K ﹤0.01% 1647
2024
Q4
$425K Sell
8,879
-510
-5% -$26.2K ﹤0.01% 1802
2024
Q3
$537K Sell
9,389
-1,417
-13% -$81.2K ﹤0.01% 1691
2024
Q2
$566K Sell
10,806
-2,755
-20% -$121K ﹤0.01% 1623
2024
Q1
$552K Buy
+13,561
New +$508K ﹤0.01% 1636

Other funds holding HALO

Pathstone Holdings's HALO Position: Q2 2026 in Review

Pathstone Holdings increased its Halozyme (HALO) stake by 3% in Q2 2026, buying an estimated $17.1K and bringing the position to 8,620 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

Pathstone Holdings first reported a position in HALO in Q1 2024 and has held it in 10 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Pathstone Holdings held 8,620 shares of Halozyme worth $675K as of Q2 2026.
  • Pathstone Holdings bought 251 Halozyme shares in Q2 2026, an estimated $17.1K.
  • Halozyme made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1716 holding.
  • Pathstone Holdings first reported a position in Halozyme in Q1 2024 and has held it in 10 quarters since.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.